Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: UK To Speed Up Trials Of New Drugs, Expands Use Of Tocilizumab

Executive Summary

AstraZeneca and BioNTech are both boosting production of their vaccines in Europe, and the first batches of Comirnaty have arrived in Australia and New Zealand.

You may also be interested in...



UK Gathers Global Leaders For Pandemic Preparedness Project

New government funding to boost vaccine manufacturing and research into variant vaccines is being made available as part of the UK’s ambitious plans for a partnership to accelerate the availability of vaccines and other products for future pandemics.

Russians Attack 'Negative' EMA Comments On National Sputnik V Authorizations

Politics are never far from the surface where coronavirus vaccines are concerned, as demonstrated by recent comments by the Sputnik V developers. 

More Good News On Actemra In Severe COVID-19 – But Will Roche File For Approval?

The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete its own studies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel